InsiderSignal.AI

InsiderSignal.ai

RVMD - Revolution Medicines, Inc.

Insider Sale by Kelsey Stephen Michael (See Remarks)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

6 days ago, Kelsey Stephen Michael, serving as See Remarks at Revolution Medicines, Inc. (RVMD), sold 4,302 shares at $99.48 per share, for a total transaction value of $427,965.00. Following this transaction, Kelsey Stephen Michael now holds 295,398 shares of RVMD.

This sale represents a 1.00% decrease in Kelsey Stephen Michael's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, March 17, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, March 19, 2026, 2 days after the trade was made.

Revolution Medicines, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Kelsey Stephen Michael

Kelsey Stephen Michael

See Remarks

Stephen (Steve) Kelsey, M.D., MB ChB, FRCP, FRCPath is a distinguished physician-scientist and oncologist serving as President, Research & Development at Revolution Medicines, Inc. (NASDAQ: RVMD), a precision oncology company based in Redwood City, California, since 2017.[[1]](https://www.delphiatx.com/team/steve-kelsey-m-d/)[[2]](https://www.autobahn-labs.com/steve-kelsey-m-d/)[[6]](https://www.revmed.com/team/steve-kelsey-m-d/) In this role, he oversees the development of innovative cancer therapeutics targeting RAS mutations and other oncology programs.[[2]](https://www.autobahn-labs.com/steve-kelsey-m-d/)[[7]](https://www.revmed.com/about/) Recently, as a corporate insider listed as 'See Remarks,' he sold approximately $5.5 million in RVMD shares across multiple transactions in September, exercising options for 125,000 shares while retaining direct ownership of 289,414 shares including restricted stock units.[[4]](https://www.investing.com/news/insider-trading-news/revolution-medicines-exec-kelsey-sells-55m-in-shares-93CH-4239687) Kelsey brings over 22 years of biopharmaceutical experience, with key career highlights including leadership in the development of oncology drugs such as Sutent® (sunitinib) at Pharmacia/SUGEN (acquired by Pfizer), Perjeta®, Kadcyla®, and Erivedge® at Genentech, and imetelstat at Geron.[[1]](https://www.delphiatx.com/team/steve-kelsey-m-d/)[[2]](https://www.autobahn-labs.com/steve-kelsey-m-d/)[[3]](https://circlepharma.com/circle-pharma-appoints-stephen-kelsey-mb-chb-md-to-its-board-of-directors) His prior roles encompass President of Onkaido Therapeutics (Moderna venture focused on oncology mRNA), senior positions at Medivation and Geron, Vice President of Hematology/Oncology at Genentech, and he currently serves on boards including Delphia Therapeutics and Circle Pharma.[[1]](https://www.delphiatx.com/team/steve-kelsey-m-d/)[[3]](https://circlepharma.com/circle-pharma-appoints-stephen-kelsey-mb-chb-md-to-its-board-of-directors)[[5]](https://www.biospace.com/press-releases/delphia-therapeutics-appoints-leading-cancer-expert-steve-kelsey-m-d-to-board-of-directors)

View full insider profile →

Trade Price

$99.48

Quantity

4,302

Total Value

$427,965.00

Shares Owned

295,398

Trade Date

Tuesday, March 17, 2026

6 days ago

SEC Filing Date

Thursday, March 19, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Revolution Medicines, Inc.

Company Overview

No company information available
View news mentioning RVMD

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4923353

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime